Cellectis Shares Preclinical Data, Plans China Trial for 2027

Cellectis presented expanded preclinical data for HEAL-101, an APOC3 base editor, and plans to start a Phase 1 investigator-initiated trial in China, with preliminary data expected in H2 2027.